“Entering the Clinic with AX-0810: Establishing Safety, PK, and the Biomarker Roadmap for Proof of Target Engagement”

Join ProQR Therapeutics for a virtual investor and analyst event featuring presentations by ProQR Management and key opinion leader (KOL) Professor Henkjan J. Verkade, MD, PhD, a pediatric gastro/hepatologist at the Beatrix Children’s Hospital of the University Medical Center Groningen.

The event will review ProQR’s Phase 1 study of AX-0810 in healthy volunteers, recently authorized by the Central Committee on Research Involving Human Subjects (CCMO) under the EMA centralized process. AX-0810 is ProQR’s lead investigational editing oligonucleotide (EON) targeting NTCP, being developed for the treatment of cholestatic diseases like primary sclerosing cholangitis (PSC) and biliary atresia.

A live question and answer session with management and covering analysts will follow the formal presentations.